News from all angles
(MedPage Today) -- The FDA granted accelerated approval to the third-generation ALK inhibitor neladalkib (Nelkarmi) for previously treated advanced ALK-positive non-small cell lung cancer (NSCLC), ma…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network